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SHORT COMMUNICATION
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ABSTRACT
Nine indole derivatives (9a-i) were tested as potential inhibitors of the Keap1–Nrf2 interaction. This class
of compounds increases the intracellular levels of the transcription factor Nrf2 and the consequent expres-
sion of enzymes encoded by genes containing the antioxidant response element (ARE). In the ARE-lucifer-
ase reporter assay only 9e-g revealed to be remarkably more active than t-butylhydroxyquinone (t-BHQ),
with 9g standing out as the best performing compound. While 9e and 9f are weak acids, 9g is an ampho-
lyte prevailing as a zwitterion in neutral aqueous solutions. The ability of 9e-g to significantly increase
levels of Nrf2, NADPH:quinone oxidoreductase 1, and transketolase (TKT) gave further support to the
hypothesis that these compounds act as inhibitors of the Keap1–Nrf2 interaction. Docking simulations
allowed us to elucidate the nature of the putative interactions between 9g and Keap1.
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The interaction between Kelch-like ECH-associated protein 1
(Keap1)1 and the Nuclear Factor Erythroid 2-Related Factor 2
(Nrf2)2 plays a crucial role in the homeostasis of cellular oxidative
stress3. Under physiological conditions, the activity of Nrf2 as a
transcription factor is negatively regulated by Keap1 through pro-
teasomal degradation mechanisms4. An increase of the intracellu-
lar levels of reactive oxygen species (ROS) interferes with the
stability of the Keap1–Nrf2 complex – situated in the cytoplasm –
by oxidation of cysteine residues located in a specific domain of
Keap1. Disruption of the stability of the Keap1–Nrf2 complex trig-
gers the release of Nrf2, allowing this protein to reach the nucleus
where it behaves as a transcriptional activator of genes that con-
tain the enhancer sequence antioxidant response element (ARE)5.
As a result, several enzymes, such as NADPH:quinone oxidoreduc-
tase 1 (NQO1), heme oxygenase-1 (HO-1), glutathione
S-transferase (GST), superoxide dismutase (SOD), catalase (CAT),
and transketolase (TKT) are overexpressed6–8. These antioxidant
enzymes reduce oxidative stress and, consequently, limit cellular
damages. Thus, the Keap1–Nrf2-ARE system plays a pivotal role in
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cellular metabolism and redox balance. For the above reasons,
inhibitors of the Keap1–Nrf2 interaction are currently being inves-
tigated as potential drugs to treat diseases involving chronic
oxidative stress, such as diabetes, cancer and neurodegenera-
tive disorders9.
The first non-peptide small molecules disrupting the
Keap1–Nrf2 interaction by binding to Keap1 with micromolar affin-
ities were reported by Hu et al.10 and Marcotte et al.11 using high
throughput screening methods. This latter group also solved the
3D structures of two ligand-Keap1 complexes by X-ray crystallog-
raphy11. The above quoted works gave impetus to additional
X-ray diffraction studies and researches aimed at identifying novel
ligands of Keap112.
According to Jiang et al.12, the Keap1 binding cavity hosting
inhibitors of the Keap1–Nrf2 interaction can be divided into six
subpockets (P1–P6). P1 and P2 contain protonated arginine resi-
dues (R483, R415, R380) which give rise to strong electrostatic
interactions with electron-rich parts of ligands; specifically, salt
bridges with carboxylate groups, H-bonds with nitro oxygens or
azole nitrogens, cation–p contacts with aromatic rings. Additional
polar as well as hydrophobic interactions are established between
ligands and the complementary Keap1 binding cavity. Some inhib-
itors of the Keap1–Nrf2 interaction, representative of the variety of
a huge number of those reported in literature10–16 are reported in
Chart 1. They typically contain in their structures a planar or
quasi-planar scaffold bearing at least one aromatic ring involved
in cation–p interactions.
Our research group has been working for several years on dif-
ferent series of indole derivatives each of them binding with high
potency and selectivity to the benzodiazepine receptor17, the A2B
adenosine receptor18 and the translocator protein19. Given the
commonly ascertained utility of indole as a scaffold for drug-like
molecules (see compound 4 in Chart 1), we tried to identify novel
indole derivatives which could act as inhibitors of the Keap1–Nrf2
interaction with the help of molecular modelling and substructure
search methods. Specifically, a few indole-bearing models were
superimposed on available 3D structures of inhibitors of the
Keap1–Nrf2 interaction co-crystallised with Keap1. Starting from
some designed indole derivatives we identified commercially avail-
able compounds using the SciFinder20 substructure search routine.
Examples of the above approaches are given in the Supporting




Nine indole derivatives fulfilling the pharmacophoric requirements
to act as inhibitors of the Keap1–Nrf2 interaction12 were selected
for biological evaluation (9a-i reported in Chart 2). Compounds
9a-d were synthesised (see Supporting Information), whereas 9e-i
were purchased from AKos (AKos GmbH, Steinen, Germany).
Based on their acid-basic properties, these compounds can be div-
ided into three groups: (a) non-ionisable (9a-d); (b) acidic (9e, f);
ampholytic (9g-i). We reasoned that the presence of methoxy
group(s) or a methylendioxy moiety on the benzene rings in the
structures of the selected compounds might allow them to inter-
act with Keap1 through cation–p interactions and H-bonds. The
thiophene ring featured by 9e-g confers more conformational
rigidity to the above compounds and an electron-rich ring capable
to establish cation–p interactions.
Biology
The biology experiments are detailed in the Supporting
Information. To evaluate the capability of the indole derivatives
9a-i to inhibit the Keap1–Nrf2 interaction, we performed a cell-
based luciferase reporter assay in which induction of ARE-driven
luciferase activity is mediated by Nrf2. HeLa cells were transiently
transfected with ARE-luciferase reporter plasmids and treated with
all compounds at the concentration of 10 lM, except for 9g which
was tested at the concentration of 5 lM owing to its limited solu-
bility in phosphate buffer. t-Butylhydroxyquinone (t-BHQ), one of
the canonical activators of Nrf212,21,22, was employed as a positive
Chart 1. Structures of representative inhibitors of the Keap1–Nrf2 interaction. For each compound a reference is reported in parentheses. Compounds 6 and 8 exhibit
nanomolar affinities for Keap1, whereas the remaining compounds bind to Keap1 with micromolar affinities.
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control at the concentration of 50mM, a value which induced in
our experiments the maximum luciferase activity.
Compounds 9e, 9f, and 9g increased luciferase activity by 152,
263, and 486%, respectively (Figure 1). Compared with the activity
exhibited by t-BHQ (48% increase), the activities of 9e-g were
higher by 3.2-, 5.5-, and respectively, 10.1-folds. The remaining
compounds displayed poor activities in this assay, comparable or
lower with respect to t-BHQ. The best performing compounds
9e-g share a common thiophene-carboxylic moiety. Among this
subset, 9e and 9f are acidic, whereas 9g – by far the most active
compound – is ampholytic.
To assess the inhibition of the Keap1–Nrf2 interaction exerted
by 9e-g, we evaluated the expression of Nrf2 and of two enzymes
encoded by its downstream target ARE genes, namely NQO1 and
TKT. Hela cells were treated with 9e and 9f at the concentration
of 10 mM while 9g was employed at the concentration of 5 mM.
We used t-BHQ as a reference compound at the concentration of
50 mM. As shown in Figure 2, expression of NQO1 and of TKT
remarkably increased after treatment with 9e-g. In Figure 2, it can
be appreciated a significant increase in Nrf2 levels determined by
our indole derivatives, clearly much higher compared to that pro-
duced by t-BHQ. The original picture of the Western blot gel is
reported in the Supporting Information.
Compounds 9e-g, selected as the most active indole deriva-
tives in the luciferase assay, were evaluated for their cytotoxicity
after 72 h of incubation in human peripheral blood lymphocytes
(PBLs) (Table S1). The compounds were tested either in quiescent
and in proliferating PBLs (proliferation was induced by phytohe-
matoagglutinin (PHA) as a mitogenic stimulus).
The obtained data indicate that the above compounds can be
considered safe for human cells. In the absence of PHA, 9e, f
exhibited GI50 values greater than 100 mM, while 9g showed GI50
values greater than 5 mM (higher concentrations of this compound
could not be used due to its limited solubility in phosphate
Chart 2. Structures of the indole derivatives selected as potential inhibitors of the Keap1–Nrf2 interaction.
Figure 1. Increase of luciferase activity in HeLa cells transfected transiently with
ARE-luciferase reporter plasmids after 24 h of treatment with 10mM of the indi-
cated compounds, except for 9g tested at the concentration of 5mM due to its
limited solubility in phosphate buffer. Data are expressed as mean±SEM of two
independent experiments performed in duplicate.
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buffer). Compounds 9e, f slightly increased their cytotoxicity in
proliferating PBLs showing GI50 values of 61.0lM and, respect-
ively, 84.9mM. Compound 9g killed 6 and 10% of quiescent and,
respectively, proliferating PBLs.
Molecular modelling
The potential interactions of 9g with Keap1 were modelled in sil-
ico by docking simulations. Details of these calculations are avail-
able in the Supporting Information. Compound 9g was treated as
a zwitterion, as this species prevails to a significant extent either
in neutral aqueous solutions or in the essentially polar environ-
ment of the Keap1 binding cavity. As represented in Figures 3
and 4, in our docking model the ligand occupies the central cavity
of Keap1 with the carboxylate group pointing outwards and the
rest of the molecule extending into the central channel of the
protein. Based on the partition of the Keap1 binding cavity pro-
posed by Jiang et al.12 into subpockets P1–P6, 9g seemingly occu-
pies mainly P1 and part of P2 and P3, taking into account that
arginine 415 is located at the border of P1 and P2.
Several strong electrostatic ligand–protein interactions take
place: the carboxylate of 9g forms a salt bridge with the arginine
483 side chain and a charge-reinforced H-bond with the P1 serine
508 side chain; the thiophene ring of the ligand establishes a cati-
on–p interaction with the arginine 415 side chain (subpockets P1
and P2). Weaker hydrophobic interactions contribute to the lig-
and-protein affinity through favorable contacts between the
indole nucleus of the ligand with the P3 alanine 556 methyl group
and the arginine 415 dimethylene fragment.
The (m-methoxy)benzylaminomethyl substituent, in its proto-
nated state, points deep down into the central Keap1 channel
where it establishes hydrophobic interactions with valine 512 and
leucine 472 side chains and a H-bond between the m-methoxy
oxygen and the leucine 472 backbone NH.
The results of our theoretical calculations suggest that the thio-
phene ring featured by 9e-g, engaged in a strong cation–p inter-
action, is responsible for their considerable activities as inducers
of antioxidant enzymes. This hypothesis is consistent with the
much lower activities exhibited by 9h and 9i in which a dimethy-
lene and, respectively, a trimethylene chain – in place of the thio-
phene moiety – bear a carboxyl group. However, the entropic
advantage offered by the thiophene ring in reducing the conform-
ational freedom of 9e-g with respect to 9h, i cannot be ruled out.
Discussion
The results of the biological experiments and the consistency of
our model of the 9g-Keap1 complex with SARs suggest that 9e-g
act as inhibitors of the Keap1–Nrf2 interaction. These three
Figure 3. Top (A) and front view (B) of the predicted binding conformation of 9g in complex with Keap1 extracted from the X-ray structure having PDB code 4L7B20.
In panel A, the protein is represented as cyan ribbons while the ligand as brown sticks and transparent surface. In panel B, the protein is represented as cyan sticks
and ribbons while the ligand as red sticks. H-bond interactions are evidenced with dashed blue lines.
Figure 2. Western blot analysis of Nrf2, NQO1 and TKT after 24 h of treatment of
HeLa cells with the indicated compounds. Compounds 9e and 9f were used at
the concentration of 10mM, whereas 9g was used at the concentration of 5mM
due to its limited solubility in phosphate buffer. t-BHQ was used at the concen-
tration of 50mM as a positive control. To confirm equal protein loading, each
membrane was stripped and reprobed with anti-b-actin antibody.
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compounds share a thiophene-carboxylate moiety which gives
rise to putative strong electrostatic interactions with arginine 483
and serine 508 of Keap1 and, additionally, limits conform-
ational freedom.
Acidic inhibitors of the Keap1–Nrf2 interaction bearing carbox-
ylic groups exist in aqueous neutral solution mainly as anionic
species. This have been considered an obstacle to translocation
into cells15,23. To circumvent such a problem, bioisosteric replace-
ments of a carboxylic group with a tetrazole ring24 or a nitro
group16 have been attempted, yielding compounds which
retained high affinity for Keap1 and exhibited improved activity in
cell-based experiments. Compound 9g stands out as the most
active indole derivatives among those investigated. To our know-
ledge, 9g represents the first inhibitor of the Keap1–Nrf2 inter-
action with ampholytic properties.
Several physicochemical and pharmacokinetic properties of 9a-
i were calculated using the Maestro QikProp tool25 (Table S1). The
drug-likeness of the compounds is indeed confirmed by these
data that show a negligible number of Lipinski Rule of 5 and
Jorgensen Rule of 3 violations, good oral absorption and a preva-
lently lipophilic profile for each of them.
The data reported in the present paper, together with the
docking model of 9g-Keap1 complex, will be exploited for con-
tinuing the design and the synthesis of novel indole derivatives as
inhibitors of the Keap1–Nrf2 interaction.
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